Risankizumab Bests Ustekinumab in Head-to-Head SEQUENCE Trial

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Related Keywords

France ,Laurent Peyrin Biroulet ,Roopal Thakkar ,Drug Administration ,Johnson ,Development In Regulatory Affairs ,University Hospital Of Nancy ,Image Analysis Group Laurent Peyrin Biroulet ,News Center ,Infinity Institute ,Image Analysis Group ,University Hospital ,Simple Endoscopy Score ,Regulatory Affairs ,Met All Primary ,Secondary Endpoints Versus Stelara ,Head To Study ,Only Specific ,Treat Moderately ,Severely Active Crohn ,Adults With Moderately ,Comparing Intravenous ,Assess Change ,Disease Activity Index ,Adult Participants With Moderate ,Severe Crohn ,Crohn Disease ,Crohn X27s Disease ,Cd ,Risankizumab ,Bustekinumab ,Phase 3 ,Clinical ,Trial ,Sequence ,Anti Tnf ,